Neurodevelopment of Psychotic Disorders
- Ripke S.
- Walters J.T.
- O’Donovan M.C.
Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia.
Early Phase of Illness
- Koutsouleris N.
- Kambeitz-Ilankovic L.
- Ruhrmann S.
- Rosen M.
- Ruef A.
- Dwyer D.B.
- et al.
- Tognin S.
- van Hell H.H.
- Merritt K.
- Winter-van Rossum I.
- Bossong M.G.
- Kempton M.J.
- et al.
Importance of Early Intervention
Early Psychosis Program Directory..
Prior Phase-Specific Model of SZ Pathophysiology
Normal and Abnormal Development, Focusing on PFC Dopamine D1 System
- Heng L.J.
- Markham J.A.
- Hu X.T.
- Tseng K.Y.
Updated Model Incorporating Dopamine Systems
Application of the Developmental Model to Illness Phase and Potential Interventions
Unique Challenges and Opportunities in Early Psychosis Assessment and Treatment
Stage-Specific Screening, Assessment, and Ttreatment
Core Assessment Battery (CAB).
Potential Role of Biomarkers in EP Assessment
Acclerated Medicines Partnership. Schizophrenia.
Implementing Biomarkers Into CSC for EP and Potential Novel Compounds
- Egerton A.
- Murphy A.
- Donocik J.
- Anton A.
- Barker G.J.
- Collier T.
- et al.
- Egerton A.
- Murphy A.
- Donocik J.
- Anton A.
- Barker G.J.
- Collier T.
- et al.
- Koutsouleris N.
- Kambeitz-Ilankovic L.
- Ruhrmann S.
- Rosen M.
- Ruef A.
- Dwyer D.B.
- et al.
Acknowledgments and Disclosures
- Infant predictors of the longitudinal course of schizophrenic development.Schizophr Bull. 1987; 13: 395-409
- Neuromotor precursors of schizophrenia.Schizophr Bull. 1994; 20: 441-451
- A prospective cohort study of neurodevelopmental processes in the genesis and epigenesis of schizophrenia.Dev Psychopathol. 1999; 11: 467-485
- Cerebral ventricular size and cognitive impairment in chronic schizophrenia.Lancet. 1976; 2: 924-926
- Obstetric complications, neurodevelopmental deviance, and risk of schizophrenia.J Psychiatr Res. 1987; 21: 413-421
- Implications of normal brain development for the pathogenesis of schizophrenia.Arch Gen Psychiatry. 1987; 44: 660-669
- Reinventing schizophrenia. Updating the construct.Schizophr Res. 2022; 242: 1-3
- Eye-tracking dysfunctions in schizophrenic patients and their relatives.Arch Gen Psychiatry. 1974; 31: 143-151
- Young psychophysiologist award address, 1982. Psychophysiology and genetics: A key to psychopathology research.Psychophysiology. 1983; 20: 371-383
- Deficits in sensory gating in schizophrenic patients and their relatives. Evidence obtained with auditory evoked responses.Arch Gen Psychiatry. 1984; 41: 607-612
- Working memory impairments in schizophrenia: A meta-analysis.J Abnorm Psychol. 2005; 114: 599-611
- The Consortium on the Genetics of Schizophrenia: Neurocognitive endophenotypes.Schizophr Bull. 2007; 33: 49-68
- Recent advances in the genetics of schizophrenia.Mol Neuropsychiatry. 2018; 4: 35-51
- Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia.medRxiv. 2020; https://doi.org/10.1101/2020.09.12.20192922
- Deconstructing vulnerability for psychosis: Meta-analysis of environmental risk factors for psychosis in subjects at ultra high-risk.Eur Psychiatry. 2017; 40: 65-75
- Gene-environment interactions in schizophrenia: A literature review.Genes (Basel). 2021; 12: 1850
- Markers of psychosis risk in the general population.Biol Psychiatry. 2020; 88: 337-348
- The Psychosis-Risk Syndrome: Handbook for Diagnosis and Follow-Up.Oxford University Press, New York2010
- Ultra-high-risk paradigm: Lessons learnt and new directions.Evid Based Ment Health. 2018; 21: 131-133
- Identification of young people at risk of psychosis: Validation of Personal Assessment and Crisis Evaluation Clinic intake criteria.Aust N Z J Psychiatry. 2000; 34: S164-S169
- Predicting psychosis: Meta-analysis of transition outcomes in individuals at high clinical risk.Arch Gen Psychiatry. 2012; 69: 220-229
- Clinical staging of psychiatric disorders: A heuristic framework for choosing earlier, safer and more effective interventions.Aust N Z J Psychiatry. 2006; 40: 616-622
- Why we need a transdiagnostic staging approach to emerging psychopathology, early diagnosis, and treatment.JAMA Psychiatry. 2016; 73: 191-192
- Transdiagnostic clinical staging in youth mental health: A first international consensus statement.World Psychiatry. 2020; 19: 233-242
- Clinical staging in psychiatry: A cross-cutting model of diagnosis with heuristic and practical value.Br J Psychiatry. 2013; 202: 243-245
- Advances in clinical staging, early intervention, and the prevention of psychosis.F1000Res. 2019; 8 (Faculty Rev-2027): F1000
- An individualized risk calculator for research in prodromal psychosis.Am J Psychiatry. 2016; 173: 980-988
- Development and validation of a clinically based risk calculator for the transdiagnostic prediction of psychosis.JAMA Psychiatry. 2017; 74: 493-500
- External validation and extension of the NAPLS-2 and SIPS-RC personalized risk calculators in an independent clinical high-risk sample.Psychiatry Res. 2019; 279: 9-14
- Calculating individualized risk components using a mobile app-based risk calculator for clinical high risk of psychosis: Findings from ShangHai At Risk for Psychosis (SHARP) program.Psychol Med. 2021; 51: 653-660
- Prediction of psychosis in prodrome: Development and validation of a simple, personalized risk calculator.Psychol Med. 2019; 49: 1990-1998
- Development of a probability calculator for psychosis risk in children, adolescents, and young adults [published online ahead of print Jan 12].Psychol Med. 2021;
- Prediction models of functional outcomes for individuals in the clinical high-risk state for psychosis or with recent-onset depression: A multimodal, multisite machine learning analysis.JAMA Psychiatry. 2018; 75: 1156-1172
- Towards precision medicine in psychosis: Benefits and challenges of multimodal multicenter studies-PSYSCAN: Translating neuroimaging findings from research into clinical practice.Schizophr Bull. 2020; 46: 432-441
- Pluripotential risk and clinical staging: Theoretical considerations and preliminary data from a transdiagnostic risk identification approach.Front Psychiatry. 2020; 11553578
- Diagnostic shifts during the decade following first admission for psychosis.Am J Psychiatry. 2011; 168: 1186-1194
- Annual Research Review: Prevention of psychosis in adolescents - systematic review and meta-analysis of advances in detection, prognosis and intervention.J Child Psychol Psychiatry. 2021; 62: 657-673
- Pennsylvania coordinated specialty care programs for first-episode psychosis: 6- and 12-month outcomes.Early Interv Psychiatry. 2021; 15: 1395-1408
- Results of a coordinated specialty care program for early psychosis and predictors of outcomes.Psychiatr Serv. 2018; 69: 863-870
- Preliminary evaluation of Washington State's Early Intervention Program for First-Episode Psychosis.Psychiatr Serv. 2020; 71: 228-235
- Stigma toward psychosis and its formulation process: Prejudice and discrimination against early stages of schizophrenia.Compr Psychiatry. 2017; 73: 181-186
- Does active psychosis cause neurobiological pathology? A critical review of the neurotoxicity hypothesis.Psychol Med. 2014; 44: 1577-1590
- Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: A critical review and meta-analysis.Am J Psychiatry. 2005; 162: 1785-1804
- Associations between duration of untreated psychosis and domains of positive and negative symptoms persist after 10 years of follow-up: A secondary analysis from the OPUS trial.Schizophr Res. 2021; 228: 575-580
- Comprehensive versus usual community care for first-episode psychosis: 2-Year outcomes from the NIMH RAISE Early Treatment Program.Am J Psychiatry. 2016; 173: 362-372
- Symptom remission at 12-weeks strongly predicts long-term recovery from the first episode of psychosis.Psychol Med. 2020; 50: 1452-1462
- Remission and recovery from first-episode psychosis in adults: Systematic review and meta-analysis of long-term outcome studies.Br J Psychiatry. 2017; 211: 350-358
- Effectiveness of antipsychotics used in first-episode psychosis: A naturalistic cohort study.BJPsych Open. 2016; 2: 323-329
- Comparison of early intervention services vs treatment as usual for early-phase psychosis: A systematic review, meta-analysis, and meta-regression.JAMA Psychiatry. 2018; 75: 555-565
- Ten-year follow-up of the OPUS specialized early intervention trial for patients with a first episode of psychosis.Schizophr Bull. 2015; 41: 617-626
- Early Psychosis Program Directory..(Available at:)
- Clinical predictors of therapeutic response to antipsychotics in schizophrenia.Dialogues Clin Neurosci. 2014; 16: 505-524
- Very low-dose risperidone in first-episode psychosis: A safe and effective way to initiate treatment.Schizophr Res Treatment. 2011. 2011; 631690
- Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia.Biol Psychiatry. 2015; 78: 754-762
- Toward illness phase-specific pharmacotherapy for schizophrenia.Biol Psychiatry. 2015; 78: 738-740
- Cortical disinhibition in the neonatal ventral hippocampal lesion model of schizophrenia: New vistas on possible therapeutic approaches.Pharmacol Ther. 2012; 133: 19-25
- Dysregulation of midbrain dopamine system and the pathophysiology of schizophrenia.Front Psychiatry. 2020; 11: 613
- Adolescence as a neurobiological critical period for the development of higher-order cognition.Neurosci Biobehav Rev. 2018; 94: 179-195
- Postnatal maturation of the dopaminergic innervation of monkey prefrontal and motor cortices: A tyrosine hydroxylase immunohistochemical analysis.J Comp Neurol. 1995; 358: 383-400
- Adolescent neurodevelopment and vulnerability to psychosis.Biol Psychiatry. 2021; 89: 184-193
- Dynamic mapping of human cortical development during childhood through early adulthood.Proc Natl Acad Sci U S A. 2004; 101: 8174-8179
- Cortical inhibitory neurons and schizophrenia.Nat Rev Neurosci. 2005; 6: 312-324
- Dopamine's actions in primate prefrontal cortex: Challenges for treating cognitive disorders.Pharmacol Rev. 2015; 67: 681-696
- Developmental changes in human dopamine neurotransmission: Cortical receptors and terminators.BMC Neurosci. 2012; 13: 18
- Dopamine modulation of prefrontal cortex interneurons occurs independently of DARPP-32.Cereb Cortex. 2008; 18: 951-958
- Dopamine increases inhibition in the monkey dorsolateral prefrontal cortex through cell type-specific modulation of interneurons.Cereb Cortex. 2007; 17: 1020-1032
- Mechanisms of dopamine activation of fast-spiking interneurons that exert inhibition in rat prefrontal cortex.J Neurophysiol. 2002; 88: 3150-3166
- Concurrent upregulation of postsynaptic L-type Ca(2+) channel function and protein kinase A signaling is required for the periadolescent facilitation of Ca(2+) plateau potentials and dopamine D1 receptor modulation in the prefrontal cortex.Neuropharmacology. 2011; 60: 953-962
- High frequency stimulation-induced plasticity in the prelimbic cortex of rats emerges during adolescent development and is associated with an increase in dopamine receptor function.Neuropharmacology. 2018; 141: 158-166
- Alteration of dopamine D1 receptor-mediated motor inhibition and stimulation during development in rats is associated with distinct patterns of c-fos mRNA expression in the frontal-striatal circuitry.Eur J Neurosci. 2004; 19: 945-956
- A schizophrenia-related deletion leads to KCNQ2-dependent abnormal dopaminergic modulation of prefrontal cortical interneuron activity.Cereb Cortex. 2018; 28: 2175-2191
- Dopamine affects parvalbumin expression during cortical development in vitro.J Neurosci. 1999; 19: 8990-9003
- Thalamic reticular nucleus impairments and abnormal prefrontal control of dopamine system in a developmental model of schizophrenia: Prevention by N-acetylcysteine.Mol Psychiatry. 2021; 26: 7679-7689
- Age- and sex-specific effects of stress on parvalbumin interneurons in preclinical models: Relevance to sex differences in clinical neuropsychiatric and neurodevelopmental disorders.Neurosci Biobehav Rev. 2021; 131: 1228-1242
- Late adolescent expression of GluN2B transmission in the prefrontal cortex is input-specific and requires postsynaptic protein kinase A and D1 dopamine receptor signaling.Biol Psychiatry. 2014; 75: 508-516
- Post-pubertal emergence of prefrontal cortical up states induced by D1-NMDA co-activation.Cereb Cortex. 2005; 15: 49-57
- Dopamine D1R receptor stimulation as a mechanistic pro-cognitive target for schizophrenia.Schizophr Bull. 2022; 48: 199-210
- Neuroimaging of the dopamine/reward system in adolescent drug use.CNS Spectr. 2015; 20: 427-441
- Being right is its own reward: Load and performance related ventral striatum activation to correct responses during a working memory task in youth.Neuroimage. 2012; 61: 723-729
- Schizophrenia, dopamine and the striatum: From biology to symptoms.Trends Neurosci. 2019; 42: 205-220
- Deficits in prefrontal cortical and extrastriatal dopamine release in schizophrenia: A positron emission tomographic functional magnetic resonance imaging study.JAMA Psychiatry. 2015; 72: 316-324
- Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis.Mol Psychiatry. 2011; 16: 67-75
- Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia.Nat Neurosci. 2002; 5: 267-271
- D2 dopamine modulation of corticoaccumbens synaptic responses changes during adolescence.Eur J Neurosci. 2008; 27: 1364-1372
- Periadolescent changes of D(2) -AMPA interactions in the rat nucleus accumbens.Synapse. 2012; 66: 1-8
- Early life adversity alters the developmental profiles of addiction-related prefrontal cortex circuitry.Brain Sci. 2013; 3: 143-158
- Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: A PET study.Mol Psychiatry. 2011; 16: 885-886
- Peripubertal mGluR2/3 agonist treatment prevents hippocampal dysfunction and dopamine system hyperactivity in adulthood in MAM model of schizophrenia.Schizophr Bull. 2021; 47: 1806-1814
- Prepubertal environmental enrichment prevents dopamine dysregulation and hippocampal hyperactivity in MAM schizophrenia model rats.Biol Psychiatry. 2021; 89: 298-307
- The stress cascade and schizophrenia: Etiology and onset.Schizophr Bull. 2003; 29: 671-692
- The role of genes, stress, and dopamine in the development of schizophrenia.Biol Psychiatry. 2017; 81: 9-20
- The pathophysiological impact of stress on the dopamine system is dependent on the state of the critical period of vulnerability.Mol Psychiatry. 2020; 25: 3278-3291
- Adolescent onset of cortical disinhibition in schizophrenia: Insights from animal models.Schizophr Bull. 2011; 37: 484-492
- N-methyl-D-aspartate receptor antagonist effects on prefrontal cortical connectivity better model early than chronic schizophrenia.Biol Psychiatry. 2015; 77: 569-580
- Early-course unmedicated schizophrenia patients exhibit elevated prefrontal connectivity associated with longitudinal change.J Neurosci. 2015; 35: 267-286
- Nature of glutamate alterations in schizophrenia: A meta-analysis of proton magnetic resonance spectroscopy studies.JAMA Psychiatry. 2016; 73: 665-674
- Tuning the engine of cognition: A focus on NMDA/D1 receptor interactions in prefrontal cortex.Brain Cogn. 2007; 63: 94-122
- Clinical and functional characteristics of youth at clinical high-risk for psychosis who do not transition to psychosis.Psychol Med. 2019; 49: 1670-1677
- A case of attenuated psychosis syndrome: A broad differential diagnosis requires broad-spectrum treatment.Am J Psychiatry. 2016; 173: 321-329
- Counterpoint. Early intervention for psychosis risk syndromes: Minimizing risk and maximizing benefit.Schizophr Res. 2021; 227: 10-17
- Psychosis risk screening with the Prodromal Questionnaire--brief version (PQ-B).Schizophr Res. 2011; 129: 42-46
- The SIPS screen: A brief self-report screen to detect the schizophrenia prodrome.Schizophr Res. 2004; 70: 78
- A self-reported instrument for prodromal symptoms of psychosis: Testing the clinical validity of the PRIME Screen-Revised (PS-R) in a Japanese population.Schizophr Res. 2008; 106: 356-362
- Mapping the onset of psychosis: The Comprehensive Assessment of At-Risk Mental States.Aust N Z J Psychiatry. 2005; 39: 964-971
- Structured Clinical Interview for DSM-5, Research Version (SCID-5 for DSM-5, Research Version; SCID-5_RV).American Psychiatric Association, Arlington, VA2015
- The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.J Clin Psychiatry. 1998; 59 (Suppl 20:22-33, quiz 34-57)
- Core Assessment Battery (CAB).(Available at:)
- The Danish OPUS early intervention services for first-episode psychosis: A phase 4 prospective cohort study with comparison of randomized trial and real-world data.Am J Psychiatry. 2021; 178: 941-951
- Biomarkers in psychosis: An approach to early identification and individualized treatment.Biomark Med. 2014; 8: 51-57
- Prediction of transition from ultra-high risk to first-episode psychosis using a probabilistic model combining history, clinical assessment and fatty-acid biomarkers.Transl Psychiatry. 2016; 6: e897
- Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: Preliminary results from the NAPLS project.Schizophr Bull. 2015; 41: 419-428
- What are the functional consequences of neurocognitive deficits in schizophrenia?.American Journal of Psychiatry. 1996; 153: 321-330
- Meta-analysis of cognitive deficits in ultra-high risk to psychosis and first-episode psychosis: Do the cognitive deficits progress over, or after, the onset of psychosis?.Schizophr Bull. 2014; 40: 744-755
- Meta-analysis of cognitive performance in drug-naive patients with schizophrenia.Schizophr Res. 2014; 158: 156-162
- Phase-specific brain change of spatial working memory processing in genetic and ultra-high risk groups of schizophrenia.Schizophr Bull. 2012; 38: 1189-1199
- Spatial working memory ability is a marker of risk-for-psychosis.Psychol Med. 2003; 33: 1239-1247
- A comparative meta-analysis of neurocognition in first-degree relatives of patients with schizophrenia and bipolar disorder.Eur Psychiatry. 2017; 45: 121-128
- Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: A meta-analytic review of putative endophenotypes.Schizophr Bull. 2006; 32: 179-194
- Neurocognition in clinical high risk young adults who did or did not convert to a first schizophrenic psychosis: A meta-analysis.Schizophr Res. 2013; 149: 48-55
- Acclerated Medicines Partnership. Schizophrenia.(Available at:)https://www.nih.gov/research-training/accelerating-medicines-partnership-amp/schizophreniaDate accessed: October 28, 2022
- Early Psychosis Intervention Network.(Available at:)
- Prediction of outcome in the psychosis prodrome using neuroanatomical pattern classification.Schizophr Res. 2016; 173: 159-165
- Brain functional connectivity data enhance prediction of clinical outcome in youth at risk for psychosis.Neuroimage Clin. 2020; 26102108
- Dopamine and glutamate in antipsychotic-responsive compared with antipsychotic-nonresponsive psychosis: A multicenter positron emission tomography and magnetic resonance spectroscopy study (STRATA).Schizophr Bull. 2021; 47: 505-516
- Striatal glutamate, subcortical structure and clinical response to first-line treatment in first-episode psychosis patients.Prog Neuropsychopharmacol Biol Psychiatry. 2022; 113110473
- Mismatch negativity (MMN) as biomarker predicting psychosis in clinically at-risk individuals.Biol Psychol. 2016; 116: 36-40
- Peripheral immune markers and antipsychotic non-response in psychosis.Schizophr Res. 2021; 230: 1-8
- The role of peripheral inflammation in clinical outcome and brain imaging abnormalities in psychosis: A systematic review.Front Psychiatry. 2021; 12612471
- Topology predicts long-term functional outcome in early psychosis.Mol Psychiatry. 2021; 26: 5335-5346
- Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12 months.Eur Psychiatry. 2020; 63: e83
- Digital phenotyping: Technology for a new science of behavior.JAMA. 2017; 318: 1215-1216
- Systematic review of digital phenotyping and machine learning in psychosis spectrum illnesses.Harv Rev Psychiatry. 2020; 28: 296-304
- Actigraphy studies and clinical and biobehavioural correlates in schizophrenia: A systematic review.J Neural Transm (Vienna). 2019; 126: 531-558
- Ecological momentary assessment of everyday social experiences of people with schizophrenia: A systematic review.Schizophr Res. 2020; 216: 56-68
- Neuroinflammation and oxidative stress in psychosis and psychosis risk.Int J Mol Sci. 2017; 18: 651
- A review of molecular genetic studies of neurocognitive deficits in schizophrenia.Neurosci Biobehav Rev. 2017; 72: 50-67
- Pharmacogenetics in psychiatry: An update on clinical usability.Front Pharmacol. 2020; 11575540
- The MATRICS Consensus Cognitive Battery, part 1: Test selection, reliability, and validity.Am J Psychiatry. 2008; 165: 203-213
- The PhenX Toolkit: Get the most from your measures.Am J Epidemiol. 2011; 174: 253-260
- A cognitive neuroscience-based computerized battery for efficient measurement of individual differences: Standardization and initial construct validation.J Neurosci Methods. 2010; 187: 254-262
- Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia.Ann N Y Acad Sci. 2015; 1344: 105-119
- The auditory steady-state response (ASSR): A translational biomarker for schizophrenia.Suppl Clin Neurophysiol. 2013; 62: 101-112
- EEG microstate sequences suggest abnormally chaotic brain dynamics in psychosis.Neuropsychopharmacology. 2021; 46: 223-224
- Real-world effectiveness of antipsychotic treatment in psychosis prevention in a 3-year cohort of 517 individuals at clinical high risk from the SHARP (ShangHai At Risk for Psychosis).Aust N Z J Psychiatry. 2020; 54: 696-706
- NMDA receptor hypofunction model of schizophrenia.J Psychiatr Res. 1999; 33: 523-533
- Early detection and preventive intervention in schizophrenia: From fantasy to reality.Am J Psychiatry. 2019; 176: 794-810
- The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia.Curr Opin Pharmacol. 2018; 38: 31-36
Publication stageIn Press Corrected Proof
TRANSCENDS Group authors: Yale School of Medicine: Deepak D'Souza, Vinod Srihari, Ralitza Gueorguieva, Prashant Patel, Kimberlee Forselius-Bielen, Jing Lu, Audrey Butler, Geena Fram, Yvette Afriyie-Agyemang, Alexandria Selloni, Laura Cadavid, Sandra Gomez-Luna, Aarti Gupta, Rajiv Radhakrishnan, Ali Rashid, Ryan Aker, Philisha Abrahim, Anahita Bassir Nia, Toral Surti; Columbia University, College of Physicians and Surgeons/New York State Psychiatric Institute: Lawrence S. Kegeles, Marlene Carlson, Terry Goldberg, James Gangwisch, Erinne Benedict, Preetika Govil, Stephanie Brazis, Megan Mayer, Nathalie de la Garrigue; Stony Brook University Renaissance School of Medicine: Natalka Fallon, Topaz Baumvoll, Sameera Abeykoon, Greg Perlman, Kelly Bobchin; University of Pennsylvania, Perelman School of Medicine: Mark Elliott, Lyndsay Schmidt, Sage Rush, Allison Port, Zac Heffernan, Nina Laney, Jenna Kantor, Thomas Hohing.
User LicenseCreative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
For non-commercial purposes:
- Read, print & download
- Redistribute or republish the final article
- Text & data mine
- Translate the article (private use only, not for distribution)
- Reuse portions or extracts from the article in other works
- Sell or re-use for commercial purposes
- Distribute translations or adaptations of the article
Elsevier's open access license policy